REG - Dr. Martens PLC - Result of 2025 AGM

Dr MartensAnnouncement

10/07/2025 11:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250710:nRSJ5713Qa&default-theme=true

RNS Number : 5713Q  Dr. Martens PLC  10 July 2025

10 July 2025

DR. MARTENS PLC

RESULT OF ANNUAL GENERAL MEETING

10 JULY 2025

 

The Company announces the results of voting at its Annual General Meeting held
earlier today and confirms that all resolutions were duly passed on a poll
with majorities as set out below.

Resolutions 1 to 18 were proposed as Ordinary Resolutions and resolutions 19
to 22 as Special Resolutions.

 Resolution                                                                          Votes        %       Votes Against  %      Votes        Votes Withheld  % Voting

For

Total

                    (note 1)
            (note 2)        Capital Instructed

                                                                                   (note 1)

 01      Receive the 2025 Annual Report and Accounts                                 786,076,243  100.00  34,102         0.00   786,110,345  370,385         81.35%
 02      Approve the Directors' Remuneration Report                                  782,786,026  99.59   3,213,373      0.41   785,999,399  475,436         81.34%
 03      Approve the Final Dividend                                                  786,441,111  100.00  32,729         0.00   786,473,840  6,890           81.39%
 04      Elect Ije Nwokorie                                                          711,638,324  90.49   74,812,462     9.51   786,450,786  24,049          81.38%
 05      Elect Benoit Vauchy                                                         710,606,698  90.36   75,837,289     9.64   786,443,987  30,848          81.38%
 06      Elect Robert Hanson                                                         786,302,310  99.98   134,818        0.02   786,437,128  37,707          81.38%
 07      Re-elect Giles Wilson                                                       711,569,954  90.49   74,821,751     9.51   786,391,705  83,130          81.38%
 08      Re-elect Lynne Weedall                                                      777,807,755  98.90   8,621,954      1.10   786,429,709  45,126          81.38%
 09      Re-elect Robyn Perriss                                                      782,666,553  99.52   3,762,111      0.48   786,428,664  46,171          81.38%
 10      Re-elect Andrew Harrison                                                    782,674,150  99.52   3,768,078      0.48   786,442,228  32,607          81.38%
 11      Re-elect Ian Rogers                                                         781,923,703  99.43   4,518,525      0.57   786,442,228  32,607          81.38%
 12      Re-elect Paul Mason                                                         659,171,361  88.07   89,279,024     11.93  748,450,385  38,024,450      77.45%
 13      Re-elect Tara Alhadeff                                                      700,151,020  89.26   84,277,826     10.74  784,428,846  2,045,989       81.18%
 14      Re-appoint PricewaterhouseCoopers LLP as auditor                            786,339,031  99.99   54,271         0.01   786,393,302  81,533          81.38%
 15      Authorise the Audit & Risk Committee to determine the Auditor's             786,364,884  99.99   43,453         0.01   786,408,337  66,498          81.38%
         remuneration
 16      Approve the removal of the 5% dilution limit for discretionary share plans  785,386,811  99.87   1,055,301      0.13   786,442,112  38,618          81.38%
 17      Authorise the Company and its subsidiaries to make political donations      785,724,771  99.92   665,753        0.08   786,390,524  90,206          81.38%
 18      Authorise allotment of shares                                               783,312,171  99.62   2,997,814      0.38   786,309,985  170,745         81.37%
 19      Authorise general disapplication of pre-emption rights*                     745,894,239  94.86   40,453,577     5.14   786,347,816  127,019         81.37%
 20      Authorise additional disapplication of pre-emption rights*                  745,011,084  94.74   41,380,015     5.26   786,391,099  83,736          81.38%
 21      Authorise purchase of own shares*                                           771,750,586  98.19   14,255,925     1.81   786,006,511  474,219         81.34%
 22      Authorise calling of general meetings on 14 days' notice*                   782,554,288  99.51   3,857,228      0.49   786,411,516  63,319          81.38%

*Special Resolution

 

The votes of independent shareholders on the resolutions concerning the
election or re-election of the Independent Non-Executive Directors are set out
below:

 Resolution                        Votes        %      Votes Against  %     Votes        Votes Withheld  % Independent

For

Total

                            Capital Instructed

 06      Elect Robert Hanson       416,359,870  99.97  134,818        0.03  416,494,688  37,707          69.83%
 08      Re-elect Lynne Weedall    407,865,315  97.93  8,621,954      2.07  416,487,269  45,126          69.83%
 09      Re-elect Robyn Perriss    412,724,113  99.10  3,762,111      0.90  416,486,224  46,171          69.83%
 10      Re-elect Andrew Harrison  412,731,710  99.10  3,768,078      0.90  416,499,788  32,607          69.84%
 11      Re-elect Ian Rogers       411,981,263  98.92  4,518,525      1.08  416,499,788  32,607          69.84%

 

Notes:

1.     Votes "For" and "Against" are expressed as a percentage of votes
received.

2.     A "Vote withheld" is not a vote in law and is not counted in the
calculation of the votes "For" or "Against" a resolution.

3.     As at 6.30pm on 9 July 2025 the Company had a total of 966,341,901
ordinary shares with voting rights in issue. The total independent voting
capital, used to calculate the votes of independent shareholders on
resolutions 6 and 8 to 11, was 596,399,461.

4.     In accordance with Listing Rule 6.4.2(R), copies of the resolutions
passed as special business will shortly be available for inspection on the
National Storage Mechanism at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

 

Enquiries

Company Secretariat

Paul Rolling, Head of
Secretariat
                                +44 7584 243562

 

 

Investors and analysts
 

Bethany Barnes, Director of Investor
Relations
+44 7825 187465

 
 
 
bethany.barnes@drmartens.com

Beth Fionda, Investor Relations Manager
 
beth.fionda@drmartens.com

 

Press
 

Sodali &
Co

Ludo
Baynham-Herd

Oliver
Banks
drmartens@client.sodali.com

 
+44 207 250 1446

 

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global
presence. "Docs" or "DMs" were originally produced for their durability for
workers, before being adopted by diverse youth subcultures and associated
musical movements. Today, Dr. Martens has transcended its roots while still
celebrating its proud history. It operates in over 60 countries and employs
over 3,650 people worldwide. Its operations are split across both
Direct-to-Consumer and wholesale channels, and in addition to its
world-renowned "1460" boot its product segments span shoes including the 1461
shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as
well as a growing line of bags and accessories. Further information can be
found at https://www.drmartensplc.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSFLSUSEISEIW